Leerink Partnrs Has Pessimistic View of GPCR FY2025 Earnings

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR) – Stock analysts at Leerink Partnrs cut their FY2025 earnings per share estimates for shares of Structure Therapeutics in a research report issued to clients and investors on Monday, November 10th. Leerink Partnrs analyst D. Risinger now expects that the company will post earnings of ($1.39) per share for the year, down from their previous estimate of $1.50. The consensus estimate for Structure Therapeutics’ current full-year earnings is ($0.82) per share. Leerink Partnrs also issued estimates for Structure Therapeutics’ Q4 2025 earnings at ($0.39) EPS, FY2026 earnings at $1.08 EPS, FY2028 earnings at ($1.81) EPS and FY2029 earnings at $0.78 EPS.

Structure Therapeutics (NASDAQ:GPCR) last announced its quarterly earnings results on Thursday, November 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.01).

A number of other equities research analysts have also weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Structure Therapeutics in a report on Wednesday, October 8th. Guggenheim decreased their target price on Structure Therapeutics from $92.00 to $90.00 and set a “buy” rating on the stock in a report on Thursday, August 7th. Zacks Research cut Structure Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Friday, October 17th. Lifesci Capital upgraded Structure Therapeutics to a “strong-buy” rating in a research note on Monday, September 8th. Finally, Piper Sandler reiterated an “overweight” rating on shares of Structure Therapeutics in a report on Tuesday, October 28th. One investment analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have issued a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $68.67.

Structure Therapeutics Price Performance

GPCR traded down $0.22 during trading on Thursday, hitting $35.71. 86,084 shares of the stock traded hands, compared to its average volume of 908,484. Structure Therapeutics has a twelve month low of $13.22 and a twelve month high of $38.48. The company has a market cap of $2.06 billion, a price-to-earnings ratio of -29.36 and a beta of -1.63. The business has a 50 day moving average price of $27.24 and a 200 day moving average price of $23.20.

Institutional Trading of Structure Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jefferies Financial Group Inc. bought a new position in Structure Therapeutics during the 3rd quarter worth about $4,770,000. Rhenman & Partners Asset Management AB raised its position in shares of Structure Therapeutics by 33.3% during the third quarter. Rhenman & Partners Asset Management AB now owns 180,100 shares of the company’s stock worth $5,043,000 after acquiring an additional 45,000 shares during the last quarter. DNB Asset Management AS grew its position in shares of Structure Therapeutics by 21.2% during the 3rd quarter. DNB Asset Management AS now owns 12,888 shares of the company’s stock worth $361,000 after buying an additional 2,253 shares during the period. Private Capital Advisors Inc. bought a new stake in Structure Therapeutics in the 3rd quarter worth about $1,545,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Structure Therapeutics by 530.0% in the third quarter. EverSource Wealth Advisors LLC now owns 1,071 shares of the company’s stock valued at $30,000 after purchasing an additional 901 shares during the last quarter. 91.78% of the stock is currently owned by institutional investors and hedge funds.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.